Alcon AG: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Alcon AG Unternehmen

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.

Alcon AG Informationen



BörsenkürzelALC

Name des UnternehmensAlcon AG

IPO-datumApr 09, 2019

CEOMr. David J. Endicott

Anzahl der mitarbeiter25599

WertpapierartOrdinary Share

GeschäftsjahresendeApr 09

AddresseRue Louis d'Affry 6

StadtFRIBOURG

BörseSIX Swiss Exchange

LandSwitzerland

Postleitzahl1700

Telefon41589113800

Websitehttps://www.alcon.ch/

BörsenkürzelALC

IPO-datumApr 09, 2019

CEOMr. David J. Endicott

Führungskräfte von Alcon AG



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. David J. Endicott

Chief Executive Officer, Director

207.11K

-11.08%

Mr. Timothy C. (Tim) Stonesifer

Chief Financial Officer, Senior Vice President

134.23K

+38.34%

Mr. Rajkumar Narayanan

Senior Vice President, President - International

37.83K

+9.30%

Mr. Ian Bell

Chief Operating Officer, Senior Vice President

30.23K

-24.88%

Ms. Karen J. May, CPA

Independent Director

28.32K

+11.14%

Mr. Laurent Attias

Senior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)

22.62K

+15.19%

Mr. Scott Harlan Maw

Independent Director

17.26K

+14.57%

Ms. Ines Poeschel

Independent Director

12.08K

+15.09%

Ms. Lynn Dorsey Bleil

Independent Director

10.94K

+13.26%

Ms. Deborah Di Sanzo

Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. David J. Endicott

Chief Executive Officer, Director

207.11K

-11.08%

Mr. Timothy C. (Tim) Stonesifer

Chief Financial Officer, Senior Vice President

134.23K

+38.34%

Mr. Rajkumar Narayanan

Senior Vice President, President - International

37.83K

+9.30%

Mr. Ian Bell

Chief Operating Officer, Senior Vice President

30.23K

-24.88%

Ms. Karen J. May, CPA

Independent Director

28.32K

+11.14%

Mr. Laurent Attias

Senior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)

22.62K

+15.19%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Consumables

777.00M

30.15%

Contact lenses

692.00M

26.85%

Implantables

456.00M

17.69%

Ocular health

430.00M

16.69%

Equipment/other

222.00M

8.61%

Sales to Novartis Group

19.00M

0.74%

Nach RegionUSD

Name

Umsatz

Anteil

International

1.42B

54.99%

United States

1.16B

45.01%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Consumables

777.00M

30.15%

Contact lenses

692.00M

26.85%

Implantables

456.00M

17.69%

Ocular health

430.00M

16.69%

Equipment/other

222.00M

8.61%

Sales to Novartis Group

19.00M

0.74%

Aktionärsstatistik

Aktualisiert: Fri, Aug 15

Aktionäre

Aktionärstypen

Aktionäre

Anteil

BlackRock Advisors (UK) Limited

4.94%

The Vanguard Group, Inc.

4.13%

Aristotle Capital Management, LLC

2.41%

UBS Fund Management (Switzerland) AG

2.29%

Norges Bank Investment Management (NBIM)

2.27%

Andere

83.96%

Aktionäre

Anteil

BlackRock Advisors (UK) Limited

4.94%

The Vanguard Group, Inc.

4.13%

Aristotle Capital Management, LLC

2.41%

UBS Fund Management (Switzerland) AG

2.29%

Norges Bank Investment Management (NBIM)

2.27%

Andere

83.96%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

32.41%

Investment Advisor/Hedge Fund

25.40%

Bank and Trust

4.41%

Sovereign Wealth Fund

2.35%

Hedge Fund

2.18%

Pension Fund

1.55%

Research Firm

1.45%

Individual Investor

0.13%

Insurance Company

0.09%

Andere

30.03%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

1606

351.83M

70.41%

-6.16M

2025Q2

1631

340.08M

68.06%

-38.93M

2025Q1

1659

342.42M

68.52%

-42.21M

2024Q4

1636

370.45M

74.13%

+31.24M

2024Q3

1624

333.39M

66.72%

-2.12M

2024Q2

1594

337.16M

67.47%

-33.61M

2024Q1

1583

337.34M

67.51%

+4.25M

2023Q4

1598

326.79M

65.39%

-10.87M

2023Q3

1582

325.37M

65.11%

-21.48M

2023Q2

1575

329.22M

65.88%

-15.79M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Advisors (UK) Limited

24.68M

4.94%

--

Dec 31, 2024

The Vanguard Group, Inc.

20.64M

4.13%

+781.14K

+3.93%

Jun 30, 2025

Aristotle Capital Management, LLC

12.04M

2.41%

-191.15K

-1.56%

Jun 30, 2025

UBS Fund Management (Switzerland) AG

11.47M

2.29%

-68.71K

-0.60%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

11.35M

2.27%

-1.28M

-10.12%

Jun 30, 2025

Fidelity Management & Research Company LLC

10.21M

2.04%

-4.82M

-32.06%

Jun 30, 2025

Zürcher Kantonalbank (Asset Management)

9.14M

1.83%

+628.34K

+7.38%

Jun 30, 2025

AKO Capital LLP

7.71M

1.54%

+597.84K

+8.40%

Jun 30, 2025

Harding Loevner LP

7.01M

1.4%

-117.33K

-1.65%

Jun 30, 2025

T. Rowe Price Associates, Inc.

6.98M

1.4%

+2.06M

+41.82%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Mon, Oct 6

Name

Anteil

Franklin FTSE Switzerland ETF

2.47%

Global X Aging Population ETF

2.43%

iShares MSCI Switzerland ETF

2.3%

First Trust Indxx Medical Devices ETF

1.66%

Running Oak Efficient Growth ETF

1.64%

Global X S&P Catholic Values Developed ex-US ETF

1.04%

First Trust Switzerland Alphadex Fund

0.72%

iShares Global Healthcare ETF

0.56%

Wahed Dow Jones Islamic World ETF

0.48%

iShares ESG Advanced MSCI EAFE ETF

0.47%

Franklin FTSE Switzerland ETF

Anteil2.47%

Global X Aging Population ETF

Anteil2.43%

iShares MSCI Switzerland ETF

Anteil2.3%

First Trust Indxx Medical Devices ETF

Anteil1.66%

Running Oak Efficient Growth ETF

Anteil1.64%

Global X S&P Catholic Values Developed ex-US ETF

Anteil1.04%

First Trust Switzerland Alphadex Fund

Anteil0.72%

iShares Global Healthcare ETF

Anteil0.56%

Wahed Dow Jones Islamic World ETF

Anteil0.48%

iShares ESG Advanced MSCI EAFE ETF

Anteil0.47%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 400.00M USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Mar 01, 2022

ALC.NB Final Cash Dividend of gross CHF 0.2 paid on May 05, 2022 going ex on Apr 29, 2022

May 04, 2022

May 05, 2022

May 03, 2022

Feb 24, 2021

ALC.NB Final Cash Dividend of gross CHF 0.1 paid on May 06, 2021 going ex on May 04, 2021

May 05, 2021

May 06, 2021

May 04, 2021

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten